This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: University of Arkansas. Active years: 2010.
Company Filing History:
Years Active: 2010
Title: Innovations of Yingni Chi in Monoclonal Antibodies
Introduction
Yingni Chi is an accomplished inventor based in Little Rock, Arkansas. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on creating antibodies that can selectively recognize specific compounds, which has important implications for medical diagnostics and treatment.
Latest Patents
Yingni Chi holds a patent for monoclonal antibodies that selectively recognize methamphetamine and methamphetamine-like compounds. This invention relates to antibodies that can identify at least one compound from a group that includes (+) methamphetamine, (+) amphetamine, and (+) 3,4-methylenedioxymethamphetamine ((+) MDMA). Notably, these monoclonal antibodies do not recognize the (-) forms of methamphetamine, amphetamine, or MDMA. This innovation has the potential to enhance detection methods in various applications.
Career Highlights
Yingni Chi is affiliated with the University of Arkansas, where he conducts research and develops his innovative ideas. His work has garnered attention for its potential impact on public health and safety. With a focus on creating targeted solutions, he continues to advance the field of immunology.
Collaborations
Some of his notable coworkers include S Michael Owens and Melinda Gunnell. Their collaborative efforts contribute to the ongoing research and development in the field of monoclonal antibodies.
Conclusion
Yingni Chi's contributions to the development of monoclonal antibodies represent a significant advancement in biotechnology. His innovative work has the potential to improve diagnostic methods and enhance public health initiatives.